Ex-GSK CEO, R&D chief An­drew Wit­ty and Mon­cef Slaoui are jump­ing in­to the biotech VC game

Top phar­ma ex­ecs at the mar­quee com­pa­nies don’t re­al­ly re­tire. Some segue quite nat­u­ral­ly in­to ven­ture cap­i­tal, where their con­tacts and heavy­weight in­dus­try rep­u­ta­tions can fa­cil­i­tate the growth of lit­tle biotech com­pa­nies at a time the VC crowd is en­joy­ing a pro­longed and pop­u­lar boom.

This morn­ing two of the biggest names that once dom­i­nat­ed GSK for a decade, the new­ly re­tired CEO An­drew Wit­ty and long­time R&D chief Mon­cef Slaoui, mapped out their plans to jump in­to the biotech ven­ture cap­i­tal game. Sir An­drew has signed on as a part­ner at Durham, NC-based Hat­teras Ven­ture Part­ners, while Slaoui has joined the Eu­ro­pean team at Medicxi.

“An­drew Wit­ty we be­lieve brings the high­est lev­el of un­der­stand­ing about the phar­ma in­dus­try as a whole,” Hat­teras Gen­er­al Part­ner Bob In­gram tells me, count­ing off Wit­ty’s lead­ing roles in the glob­al com­mer­cial as well as R&D side of the busi­ness.

Wit­ty is land­ing in a group where he al­ready feels quite com­fort­able.

He joined the board at Hat­teras port­fo­lio com­pa­ny G1 re­cent­ly, re­turn­ing to a re­gion where GSK has had deep roots. He spoke at an in­vestors meet­ing in 2008 and then again last year, says In­gram, as he was wind­ing up a lengthy stint at the helm of the phar­ma gi­ant. And In­gram says Wit­ty — like­ly the on­ly knight­ed mem­ber of the biotech ven­ture com­mu­ni­ty — is ex­pect­ed to help ad­vise the firm and its biotech com­pa­nies, lend­ing some of his ster­ling Big Phar­ma rep to the or­ga­ni­za­tion as it grows up new com­pa­nies.

Just yes­ter­day Hat­teras, a big play­er in­volv­ing all things out of UNC, par­tic­i­pat­ed in a $27 mil­lion round for Cam­bridge, MA-based Rodin.

Slaoui was the long­time R&D chief at Glax­o­SmithK­line be­fore he moved to chair the big vac­cines side of the busi­ness at GSK ahead of his re­tire­ment last June. As R&D chief, Slaoui cre­at­ed the dis­cov­ery per­for­mance units that were de­signed to spur more biotech-like think­ing as the DPUs com­pet­ed for re­sources. But the DPUs failed to be­come the in­no­va­tion cen­ters that GSK need­ed — with some of Slaoui’s top bets go­ing bad — and new CEO Em­ma Walm­s­ley is fash­ion­ing her own re­or­ga­ni­za­tion to shake things up once again.

Where GSK did find ma­jor new de­vel­op­ment ini­tia­tives was in vac­cines — Shin­grix — and in HIV, where the com­pa­ny re­mains a key play­er.


The Eu­ro­pean VC firm Slaoui joined to­day has some of the best con­tacts in the in­dus­try, and a grow­ing port­fo­lio of biotechs to its cred­it. But it’s a whole dif­fer­ent world from what Slaoui helped cre­ate at GSK, which spends bil­lions of dol­lars every year on drug re­search with big op­er­a­tions in the US and UK. Medicxi’s part­ners have a rep for re­lent­less thrift, mak­ing their R&D dol­lars, eu­ros and pounds stretch as far as pos­si­ble — and then some.

In a state­ment, Slaoui said he was look­ing for­ward to start­ing, “with funds avail­able to in­vest not on­ly in ear­ly stage as­sets but al­so to build­ing in­no­v­a­tive com­pa­nies through clin­i­cal de­vel­op­ment and mar­ket en­try. I am look­ing for­ward to mak­ing an ac­tive con­tri­bu­tion to se­lect­ing and lead­ing in­vest­ments, and to sup­port­ing am­bi­tious en­tre­pre­neurs to de­vel­op med­i­cines that ul­ti­mate­ly make a dif­fer­ence to pa­tients.”

Not long af­ter leav­ing GSK, the en­thu­si­as­tic and out­go­ing Slaoui start­ed join­ing biotech boards, with wel­comes at SutroVax, mR­NA play­er Mod­er­na as well as the pub­lic out­fit In­tel­lia $NT­LA, one of a hand­ful of CRISPR/Ca9 gene edit­ing star­tups dom­i­nat­ing the field. Then, a lit­tle over a month ago, he dropped off the In­tel­lia crew, cit­ing a con­flict but not ex­plain­ing it.

We’ll see soon what he has planned in that field.


Im­ages: An­drew Wit­ty (top) Bloomberg / Mon­cef Slaoui File Pho­to

The Fac­tors Dri­ving a Rapid Evo­lu­tion of Gene & Cell Ther­a­py and CAR-T Clin­i­cal Re­search in APAC

APAC is the fastest growing region globally for cell & gene therapy trials representing more than a third of all cell & gene studies globally, with China leading in the region. 

APAC is the leading location globally for CAR-T trials with China attracting ~60% of all CAR-T trials globally between 2015-2022. The number of CAR-T trials initiated by Western companies has rapidly increased in recent years (current CAGR of about 60%), with multiple targets being explored including CD19, CD20, CD22, BCMA, CD30, CD123, CD33, CD38, and CD138.

The End­points 11; blue­bird's $3M gene ther­a­py; Bio­gen tout new neu­ro da­ta; Harsh re­views for can­cer drugs; and more

Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add Endpoints Weekly. New to Endpoints? Sign up here.

Reading about John Carroll’s pick of biotech’s most promising startups has become a treasured tradition. If you ever get curious about previous classes of the Endpoints 11, you can find all of them (plus a number of our other regular specials) here.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 150,800+ biopharma pros reading Endpoints daily — and it's free.

EMA warns of short­ages of two Boehringer heart drugs due to a spike in de­mand

The EMA is putting EU member states on alert over the shortage of two drugs that counter heart attacks due to an uptick in demand.

On Friday, the EMA sent out a warning that two Boehringer Ingelheim drugs are experiencing a shortage: Actilyse and Metalyse. The drugs are used as emergency treatments for adults experiencing acute myocardial infarction, or a heart attack, by dissolving blood clots that have formed in the blood vessels.

The End­points 11: The top pri­vate biotechs in pur­suit of new drugs. Push­ing the en­ve­lope with pow­er­ful new tech­nolo­gies

Right around the beginning of the year, we got a close-up look at what happens after a boom ripples through biotech. The crash of life sciences stocks in Q1 was heard around the world.

In the months since, we’ve seen the natural Darwinian down cycle take effect. Reverse mergers made a comeback, with more burned out shells to go public at a time IPOs and road shows are out of favor. And no doubt some of the more recent arrivals on the investing side of the business are finding greener pastures.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

Wendy Lund, WPP chief client officer for health and wellness

WPP taps Organon chief com­mu­ni­ca­tions of­fi­cer Wendy Lund for new health and well­ness client role

Wendy Lund is going home – to WPP, that is. Lund is leaving the Merck women’s health spinoff Organon where she is chief communications officer for a newly created role as WPP chief client officer for health and wellness. Before Organon, Lund led GCI Group, a WPP healthcare communications agency, as CEO for 11 years.

Lund joins WPP’s group of global client leaders who act as a single point of contact or entry for clients with WPP brands and businesses inside the holding company. and in this case, for the WPP health and wellness business.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 150,800+ biopharma pros reading Endpoints daily — and it's free.

As­traZeneca, Mer­ck cull one Lyn­parza in­di­ca­tion in heav­i­ly pre­treat­ed ovar­i­an can­cer pa­tients

Just one day after blockbuster Lynparza got access to another indication in China, its Big Pharma owners have decided to withdraw it in certain patients after reviewing Phase III data.

The two companies that work together on Lynparza decided to recall one of the indications several weeks ago in a specific type of ovarian cancer, Lynparza’s first indication when it was first FDA-approved in 2014. Initial data showed that rates of overall survival in patients with at least three rounds of chemo before getting on the PARP inhibitor were lower than in patients with less previous chemo treatment.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 150,800+ biopharma pros reading Endpoints daily — and it's free.

Fu­ji­film con­tin­ues CD­MO ex­pan­sion, break­ing ground on $435M UK site

Fujifilm’s CDMO arm, Fujifilm Diosynth, has been on a roll this month as the company has recently broken ground on a major project in Europe and it appears to be keeping up the momentum.

Fujifilm Diosynth announced that it has kicked off an expansion project for its microbial manufacturing facility at its campus in the town of Billingham, UK, in the northeast of England.

The 20,000 square-foot, £400 million ($435 million) expansion will add clean rooms, purification suites and a packing area along with more space for the manufacturing itself.

Solicitor General Elizabeth Prelogar

Should SCO­TUS hear Am­gen's Repatha case? So­lic­i­tor gen­er­al says no

Back in April, Amgen said it was encouraged by the solicitor general’s anticipated review of its Supreme Court petition to rehear a Repatha patent case. They’re likely much less optimistic about the outcome now.

Solicitor General Elizabeth Prelogar wrote in a recent 27-page brief that Amgen’s arguments “lack merit and further review is not warranted.”

The case traces back to a suit filed in 2014 against Sanofi and Regeneron’s Praluent, which ended up beating Amgen’s PCSK9 blockbuster Repatha to market by a month just a year later.

Phil Sharp, Nobel Prize laureate (L), and John Carroll, Endpoints News co-CEO (via Michael Last)

The End­points 11: Fire­side chat with No­bel Prize lau­re­ate Phil Sharp

The following Q&A has been edited for length and clarity.

John Carroll:

We’ve had a chance to talk a little bit before here about some of the things that you’ve done. Just really remarkably, a lot of the things that you’ve done early in your career puts you in the path with some amazing science that has had an absolutely huge impact in terms of what we’re seeing now on drug development and some of the new technologies that are coming out here, and not only the new technologies, but also some of the most remarkable people ever.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.